Drug intelligence / Profile preview

capecitabine + oxaliplatin + camrelizumab + cetuximab

Development stage: Unknown
Lead developer: Department of Pharmacy and Health Products
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

This combination therapy regimen consists of the CAPOX chemotherapy backbone (capecitabine and oxaliplatin) integrated with the anti-PD-1 monoclonal antibody camrelizumab and the anti-EGFR monoclonal antibody cetuximab. Developed and evaluated by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, this regimen is specifically investigated for the treatment of initially unresectable metastatic rectal cancer. The therapeutic strategy involves short-course radiotherapy followed by this four-drug combination to maximize local and systemic tumor control by leveraging cytotoxic chemotherapy, immune checkpoint inhibition, and targeted EGFR blockade in patients with KRAS/NRAS/BRAF wild-type disease.

Other names: CAPOX + Camrelizumab + CetuximabUnion-mRC regimen

Targets

TS (Thymidylate synthase)EGFR T790M (Epidermal growth factor receptor T790M mutant)PDCD1 (Programmed cell death protein 1 receptor)DNA

Beyond the preview

Go deeper on capecitabine + oxaliplatin + camrelizumab + cetuximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on capecitabine + oxaliplatin + camrelizumab + cetuximab.

Explore the full profile